Composition per capsule: Active ingredient: Umifenovir hydrochloride monohydrate (in terms of Umifenovir hydrochloride) - 100 mg.
potato starch - 30.14 mg, microcrystalline cellulose - 55.76 mg, colloidal silicon dioxide (aerosil) - 2.0 mg, povidone K 25 (collidone 25) -10.1 mg, calcium stearate - 2.0 mg Hard gelatin capsules No. 1: Case: titanium dioxide (E 171) - 2,0000%, gelatin - up to 100%. Lid: titanium dioxide (E 171) - 1.3333%, sunset sunset yellow (E 110) - 0.0044%, quinoline yellow (E 104) - 0.9197%, gelatin - up to 100%.
Antiviral agent. Specifically inhibits in vitro influenza A and B viruses (Influenzavirus A, B), including the highly pathogenic subtypes A (HINl) pdm09 and A (H5N1), as well as other viruses that cause acute respiratory viral infections (SARS) (coronavirus (Coronavirus) associated with severe acute respiratory syndrome (SARS), rhinovirus (Rhinovirus), adenovirus (Adenovirus), respiratory syncytial virus (Pneumovirus) and parainfluenza virus (Paramyxovirus)).
According to the mechanism of antiviral action, it belongs to fusion (fusion) inhibitors, interacts with the hemagglutinin of the virus and prevents the fusion of the lipid membrane of the virus and cell membranes. It has a moderate immunomodulatory effect, increases the body's resistance to viral infections.
It has interferon-inducing activity - in a study on mice, the induction of interferons was observed after 16 hours, and high titers of interferons remained in the blood up to 48 hours after administration. Stimulates cellular and humoral immunity reactions: increases the number of lymphocytes in the blood, especially T-cells (CD3), increases the number of T-helpers (CD4), without affecting the level of T-suppressors (CD8), normalizes the immunoregulatory index, stimulates macrophage phagocytic function and increases the number of natural killer cells (NK cells).
Therapeutic efficacy in viral infections is manifested in a decrease in the duration and severity of the course of the disease and its main symptoms, as well as in a decrease in the frequency of development of complications associated with a viral infection and exacerbations of chronic bacterial diseases.
In the treatment of influenza or SARS in adult patients, a clinical study showed that the effect of Arbidol in adult patients is most pronounced in the acute period of the disease and is manifested by a reduction in the resolution of symptoms of the disease, a decrease in the severity of the manifestations of the disease, and a reduction in the elimination of the virus.
Arbidol therapy leads to a higher incidence of symptoms on the third day of therapy compared to placebo. 60 hours after the start of therapy, the resolution of all symptoms of laboratory-confirmed influenza is more than 5 times higher than that in the placebo group. A significant effect of the drug Arbidol on the rate of elimination of the influenza virus was established, which, in particular, was manifested by a decrease in the frequency of detection of virus RNA on the 4th day.
Refers to low-toxic drugs (LD50> 4 g / kg). It does not have any negative effects on the human body when administered orally in recommended doses. Pharmacokinetics Quickly absorbed and distributed to organs and tissues. The maximum plasma concentration is reached after 1.5 hours.
Metabolized in the liver. The elimination half-life is 17-21 hours. About 40% is excreted unchanged, mainly with bile (38.9%) and in a small amount by the kidneys (0.12%). During the first day, 90% of the administered dose is excreted.
The drug Arbidol refers to low toxicity drugs and is usually well tolerated. Side effects are rare, usually mild or moderate, and are transient.
The frequency of adverse drug reactions is determined in accordance with the WHO classification: very often (with a frequency of more than 1/10), often (with a frequency of at least 1/100, but less than 1/10), infrequently (with a frequency of at least 1/1000, but less than 1/100), rarely (with a frequency of at least 1/10000, but less than 1/1000), very rarely (with a frequency of less than 1/10000), the frequency is unknown (cannot be established according to available data).
Disorders from the immune system: rarely - allergic reactions. If any of the side effects indicated in the instructions are aggravated, or if you notice any other side effects not listed in the instructions, inform your doctor.
Features of the sale:
It is dispensed without a prescription. Special conditions. It is necessary to observe the scheme recommended in the instructions and the duration of the drug. If you miss one dose of the drug, the missed dose should be taken as early as possible and continue the course of taking the drug according to the scheme begun.
If after using the drug Arbidol for three days in the treatment of influenza and other acute respiratory viral infections, the severity of the symptoms of the disease, including high temperature (38 ° C or more), remains, then you must consult a doctor to assess the feasibility of taking the drug. Influence on the ability to drive vehicles and other mechanisms: It does not show central neurotropic activity and can be used in medical practice as a preventive measure in healthy individuals of various professions, including requiring increased attention and coordination of movements (drivers of vehicles, operators, etc.).
Prevention and treatment in adults and children: influenza A and B, other acute respiratory viral infections. Complex therapy of recurrent herpetic infection. Prevention of postoperative infectious complications. Combined therapy of acute intestinal infections of rotavirus etiology in children over 6 years of age Contraindications
Hypersensitivity to umifenovir or any component of the drug; children under 6 years old. The first trimester of pregnancy.
The period of breastfeeding. Precautions: Second and third trimesters of pregnancy.
When prescribed with other drugs, no negative effects were noted. Special clinical studies dedicated to the study of the interactions of the drug Arbidol with other drugs have not been conducted.
Information about the presence of undesirable interactions with antipyretic, mucolytic and local vasoconstrictor drugs in a clinical trial have not been identified.
Inside, before eating. Single dose of the drug (depending on age): Age Children from 6 to 12 years old - Single dose of 100 mg (1 capsule) Children over 12 years old and adults - Single dose of 200 mg (2 capsules) Dosage regimen (depending on age): In children from 6 years of age and adults: Non-specific prophylaxis during the period of the epidemic of influenza and other acute respiratory viral infections - in a single dose 2 times a week for 3 weeks Non-specific prophylaxis in direct contact with patients with influenza and other acute respiratory viral infections in a single dose 1 time per day within 10-14 days
Treatment of influenza and other acute respiratory viral infections in a single dose 4 times a day (every 6 hours) for 5 days. Complex treatment of recurrent herpetic infection in a single dose 4 times a day (every 6 hours) for 5-7 days, then a single dose 2 times per week for 4 weeks Prevention of postoperative infectious complications in a single dose 2 days before surgery, then on the 2nd and 5th day after surgery In children from 6 years:
Combined therapy of acute intestinal infections of rotavirus etiology in a single dose 4 times a day (every 6 hours) for 5 days. Use the drug only according to the indications, the method of use and at the doses indicated in the instructions. Taking the drug begins with the onset of the first symptoms of the disease with influenza and other acute respiratory viral infections, preferably no later than 3 days from the onset of the disease.
If after using Arbi-Dol * for three days during the treatment of influenza and other acute respiratory viral infections, the severity of the symptoms of the disease, including high temperature (38 ° C or more), remains, then you must consult a doctor to assess the feasibility of taking the drug.
In the treatment of influenza and SARS, concomitant symptomatic therapy is possible, including taking antipyretic drugs, mucolytic and local vasoconstrictors.
Overdose Not marked
|Expiration Date (in months)||24|
|Country of origin||Russia|